Loading
A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Bevacizumab in cervical cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) is a phase 3 interventional study registered as NCT07216703 by Merck Sharp & Dohme LLC, with 1023 participants planned, started 2026-01-19 and due to reach its primary completion in 2031-10-29. Interventions recorded: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Bevacizumab, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Bevacizumab, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Cisplatin.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Cervical cancer.